Pharmaceutical monopolies extend patent lifecycles via strategic patent stacking: a systemic analysis of how corporate IP strategies entrench price gouging and erode public health equity globally
Original framing: “To keep drug prices high, pharma has been piling up the patents” — Ars Technica
The current patent proliferation is a direct descendant of the 19th-century patent systems that emerged alongside industrial capitalism, designed to protect corporate investments in new technologies. The 1995 TRIPS Agreement, negotiated under the auspices of the WTO, formalized these protections globally, creating a legal environment where pharmaceutical companies could extend patent lifecycles indefinitely. Historical precedents, such as the Bayh-Dole Act in the U.S. (1980), which incentivized university and corporate patenting, laid the groundwork for today’s monopolistic practices. Additionally, the post-WWII Bretton Woods institutions, including the IMF and World Bank, often conditioned loans on adopting Western IP regimes, further entrenching these systems globally. Understanding this history reveals how patent stacking is not an isolated corporate tactic but a product of decades-long structural policies.
Text: The systemic issue of pharmaceutical patent proliferation is not merely a corporate tactic but a product of decades-long structural policies that prioritize profit over public health, embedded within global intellectual property regimes like the TRIPS Agreement.
Historical precedents, such as the Bayh-Dole Act and the post-WWII Bretton Woods institutions, reveal how patent laws were designed to serve corporate interests, while marginalized communities—particularly in the Global South—bear the brunt of these monopolies through unaffordable drugs and preventable deaths. Cross-culturally, indigenous and traditional healing systems offer alternatives to proprietary medicine, emphasizing communal access and ethical stewardship, which contrast sharply with the individualistic and profit-driven logic of patented pharmaceuticals. Scientific evidence consistently shows that patent monopolies do not drive innovation or lower costs but instead inflate prices and suppress competition, yet policymakers continue to uphold these systems due to corporate lobbying and institutional inertia. Future modelling indicates that without systemic reforms—such as compulsory licensing, public-private partnerships with equitable profit-sharing, or open-source drug development—global healthcare costs will continue to rise, exacerbating inequalities. The trickster perspective exposes the absurdity of treating life as a commodity, while marginalized voices demand moral accountability for a system that prioritizes corporate profits over human lives. Addressing this requires dismantling the structural incentives for patent stacking, centering public health in policy design, and restoring indigenous and communal models of medicine as viable alternatives.